Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Dual better than triple antithrombotic therapy after percutaneous coronary intervention

10 Mar 2018

Compared to triple therapy, dual antithrombotic therapy yields reduced bleeding without excess ischaemic and thromboembolic cardiac events in patients with long-term indication to chronic oral anticoagulation (OAC) following percutaneous coronary intervention (PCI), according to a new study.

The researchers performed a meta-analysis of four randomized controlled trials (n=6,036) receiving chronic OAC after PCI. Incidences of major and minor bleeding, myocardial infarction, stroke and all-cause death, among other outcomes, were compared between those receiving dual and triple therapy.

Over the mean follow-up duration of 11.7 months, the incidence of major bleeding was 1.97 percent in patients receiving dual therapy, lower than the 3.53 percent in those on triple therapy. This finding yielded a significant 45-percent decrease in relative risk (p=0.0007).

A similar trend was observed with minor bleeding, where the relative risk was 43 percent lower with the dual vs triple therapy (3.30 percent vs 7.18 percent; p=0.00001).

Incidence of the other endpoints, such as all-cause mortality (3.81 percent vs 4.01 percent; p=0.37) and cardiovascular mortality (1.62 percent vs 2.02 percent; p=0.42) were statistically comparable between the dual and triple therapies.

“In conclusion, this large study level meta-analysis on patients candidates to OAC, mainly for AF, and undergoing PCI indicates that dual antithrombotic therapy significantly reduces major and minor bleeding compared to triple therapy,” said researchers, noting that the findings translated to 15 major and 39 minor bleeding events per 1,000 patients at 1 year, were prevented by dual therapy.

“Interestingly, the use of dual therapy led to a numerically lower mortality, although not statistically significant, probably due to the low number of events,” they added, emphasizing that limitations, such as lack of access to individual information and scarcity of available studies, warrant further, larger investigations.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.